Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives In Pharmacology, Drug Toxicity and Pharmacogenetics", celebrado en Madrid del 15 al 16 de marzo de 2018.[Introduction]: Second-generation Antipsychotics (SGAs) are preferable pharmacological treatment for patients with Schizophrenia, mainly due to their efficacy and reduced risk of extrapyramidal effects when compared with first generation antipsychotics. However, there are metabolic side effects associated with the administration of SGAs, namely weight gain, dyslipidaemia and impaired glucose metabolism. Literature reports that even in the absence of antipsychotic treatment patients with Schizophrenia have a propensity to develop metabolic ch...
Atypical antipsychotics exhibit metabolic side effects including diabetes mellitus and obesity. The ...
Background: A large body of evidence suggests that antipsychotic drugs cause body weight gain and ty...
Olanzapine is an atypical antipsychotic drug exhibiting a low incidence of extrapyramidal side effec...
Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives I...
[Objective] Metabolic syndrome is prevalent in up to 50% of schizophrenia patients, which reduces th...
Second-generation antipsychotics (SGA), especially clozapine and olanzapine, are associated with an ...
Second-generation antipsychotics (SGA), especially clozapine and olanzapine, are associated with an ...
Atypical antipsychotic (AAP) medications that have revolution-ized the treatment of mental illness h...
Treatment of schizophrenia with olanzapine and other atypical antipsychotic agents is associated wit...
Antipsychotic drug therapy is a fundamental tool in the treatment of schizophrenia and other psychos...
A growing body of literature has linked atypical antipsychotics (AAPs) to an increased propensity fo...
Atypical antipsychotics exhibit metabolic side effects including diabetes mellitus and obesity. The ...
Second generation antipsychotic (SGA) drugs represent the pharmacotherapeutic drug treatment of choi...
Artículo de publicación ISISecond generation antipsychotics (SGAs), such as clozapine, olanzapine, r...
Treatment with several antipsychotic drugs exhibits a tendency to induce weight gain and diabetic co...
Atypical antipsychotics exhibit metabolic side effects including diabetes mellitus and obesity. The ...
Background: A large body of evidence suggests that antipsychotic drugs cause body weight gain and ty...
Olanzapine is an atypical antipsychotic drug exhibiting a low incidence of extrapyramidal side effec...
Resumen del trabajo presentado al 5th Symposium on Biomedical Research: "Advances and Perspectives I...
[Objective] Metabolic syndrome is prevalent in up to 50% of schizophrenia patients, which reduces th...
Second-generation antipsychotics (SGA), especially clozapine and olanzapine, are associated with an ...
Second-generation antipsychotics (SGA), especially clozapine and olanzapine, are associated with an ...
Atypical antipsychotic (AAP) medications that have revolution-ized the treatment of mental illness h...
Treatment of schizophrenia with olanzapine and other atypical antipsychotic agents is associated wit...
Antipsychotic drug therapy is a fundamental tool in the treatment of schizophrenia and other psychos...
A growing body of literature has linked atypical antipsychotics (AAPs) to an increased propensity fo...
Atypical antipsychotics exhibit metabolic side effects including diabetes mellitus and obesity. The ...
Second generation antipsychotic (SGA) drugs represent the pharmacotherapeutic drug treatment of choi...
Artículo de publicación ISISecond generation antipsychotics (SGAs), such as clozapine, olanzapine, r...
Treatment with several antipsychotic drugs exhibits a tendency to induce weight gain and diabetic co...
Atypical antipsychotics exhibit metabolic side effects including diabetes mellitus and obesity. The ...
Background: A large body of evidence suggests that antipsychotic drugs cause body weight gain and ty...
Olanzapine is an atypical antipsychotic drug exhibiting a low incidence of extrapyramidal side effec...